Novartis Discontinues Two Drug Development Programs
Swiss pharmaceutical company Novartis announced Tuesday that it had discontinued the development of two drugs — the hepatitis C treatment Zalbin, and antifungal agent Mycograb. The company will take impairment charges of appro…